Risk factors for mortality in Stenotrophomonas maltophilia bacteremia – a meta-analysis

Figures & data

Figure 1. Flow diagram of the study selection process. *Exclude due to lack of comparison of survivors and non-survivors.

Table 1. Characteristics of the included 19 studies.

Author	Region	Study design	No. of total patients	No. of deceased patients
Chen et al. [28]	China	RET	76	26
Hotta et al. [29]	Japan	RET	54	18
Kim et al. [30]	Korea	RET	126	82
Osawa et al. [31]	Japan	RET	70	24
Ahlström et al. [37]	Denmark	RET	61	11
Araoka et al. [38]	Japan	RET	53	27
Aysert-Yildiz et al. [39]	Turkey	RET	65	33
Cho et al. [17]	Korea	RET	86	21
Ebara et al. [40]	Japan	RET	44	21
Fihman et al. [41]	France	PRO	36	11
Friedman et al. [42]	Australia	RET	8	45
Hamdi et al. [43]	USA	RET	98	29
Hashimoto et al. [44]	Japan	RET	36	11
Jeon et al. [45]	Korea	RET	142	52
Jian et al. [46]	China	RET	51	19
Kanchanasuwan et al. [47]	Thailand	RET	117	34
Metan and Uzun [48]	USA	RET	41	13
Sumida et al. [49]	Japan	RET	30	16
Watson et al. [50]	USA	RET	54	13

RET: retrospective study.PRO: prospective study.

Table 2. Risk bias of the included 19 studies.

Author	Confounding	Selection	Interventions classification	Interventions deviations	Missing data	Measurement of outcomes	Selective results
Chen et al. [28]	Low risk	Low risk	Low risk	Low risk	Low risk	Moderate risk	Low risk
Hotta et al. [29]	Low risk	Low risk	Moderate risk	Low risk	Moderate risk	Moderate risk	Moderate risk
Kim et al. [30]	Low risk	Low risk	Low risk	Low risk	Low risk	Moderate risk	Low risk
Osawa et al. [31]	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Low risk	Low risk	Moderate risk
Ahlström et al. [37]	Serious risk	Serious risk	Serious risk	Serious risk	Serious risk	Serious risk	Serious risk
Araoka et al. [38]	Serious risk	Moderate risk	Serious risk	Moderate risk	Moderate risk	Serious risk	Serious risk
Aysert-Yildiz et al. [39]	Low risk	Low risk	Moderate risk	Moderate risk	Low risk	Low risk	Low risk
Cho et al. [17]	Serious risk	Serious risk	Moderate risk	Serious risk	Moderate risk	Moderate risk	Serious risk
Ebara et al. [40]	Low risk	Low risk	Low risk	Moderate risk	Moderate risk	Moderate risk	Low risk
Fihman et al. [41]	Low risk	Low risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk
Friedman et al. [42]	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Serious risk	Serious risk	Moderate risk
Hamdi et al. [43]	Serious risk	Serious risk	Serious risk	Serious risk	Serious risk	Serious risk	Serious risk
Hashimoto et al. [44]	Serious risk	Serious risk	Moderate risk	Serious risk	Serious risk	Moderate risk	Serious risk
Jeon et al. [45]	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk
Jian et al. [46]	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Low risk	Moderate risk
Kanchanasuwan et al. [47]	Low risk	Low risk	Low risk	Moderate risk	Moderate risk	Low risk	Low risk
Metan and Uzun [48]	Serious risk	Serious risk	Serious risk	Serious risk	Moderate risk	Moderate risk	Serious risk
Sumida et al. [49]	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk	Moderate risk
Watson et al. [50]	Moderate risk	Serious risk	Moderate risk	Moderate risk	Serious risk	Serious risk	Moderate risk

Figure 2. Mortality in patients with and without polymicrobial bacteremia.

Figure 3. Mortality in patients with and without neutropenia.

Figure 4. Mortality in patients with and without ICU admission.

Figure 5. Mortality in patients with and without mechanical ventilation.

Figure 6. Mortality in patients with and without septic shock.

Figure 7. Mortality in patients with and without indwelling central venous catheter.

Figure 8. Mortality in patients with and without chronic kidney disease.

Figure 9. Mortality in patients with and without hematological malignancies.

Figure 10. Mortality in patients receiving inappropriate and appropriate antibiotic therapy.

Figure 11. Mortality in patients with and without prior antibiotic use.

Chen Y, Suo J, Du M, et al. Clinical features, outcomes, and risk factors of bloodstream infections due to Stenotrophomonas maltophilia in a tertiary-care hospital of China: a retrospective analysis. Biomed Res Int. 2019;2019:4931501–4931507. doi: 10.1155/2019/4931501.

 PubMed Web of Science ®Google Scholar

Hotta G, Matsumura Y, Kato K, et al. Risk factors and outcomes of Stenotrophomonas maltophilia bacteremia: a comparison with bacteremia caused by Pseudomonas aeruginosa and Acinetobacter species. PLOS One. 2014;9(11):e112208. doi: 10.1371/journal.pone.0112208.

 PubMed Web of Science ®Google Scholar

Kim EJ, Kim YC, Ahn JY, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 2019;19(1):754. doi: 10.1186/s12879-019-4394-4.

 PubMed Web of Science ®Google Scholar

Osawa K, Shigemura K, Kitagawa K, et al. Risk factors for death from Stenotrophomonas maltophilia bacteremia. J Infect Chemother. 2018;24(8):632–636. doi: 10.1016/j.jiac.2018.03.011.

 PubMed Web of Science ®Google Scholar

Ahlström MG, Knudsen JD, Hertz FB. Stenotrophomonas maltophilia bacteraemia: 61 cases in a tertiary hospital in Denmark. Infect Dis. 2022;54(1):26–35. doi: 10.1080/23744235.2021.

 PubMed Web of Science ®Google Scholar

Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–608. doi: 10.1007/s10096-010-0882-6.

 PubMed Web of Science ®Google Scholar

Aysert-Yildiz P, Yildiz Y, Habibi H, et al. Stenotrophomonas maltophilia bacteremia: from diagnosis to treatment. Infect Dis Clin Microbiol. 2022;4(4):258–267. doi: 10.36519/idcm.2022.187.

 Google Scholar

Cho SY, Kang CI, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim–sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1):581–583. doi: 10.1128/AAC.01682-13.

 PubMed Web of Science ®Google Scholar

Ebara H, Hagiya H, Haruki Y, et al. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Intern Med. 2017;56(2):137–142. doi: 10.2169/internalmedicine.56.6141.

 PubMed Web of Science ®Google Scholar

Fihman V, Le Monnier A, Corvec S, et al. Stenotrophomonas maltophilia – the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect. 2012;64(4):391–398. doi: 10.1016/j.jinf.2012.01.001.

 PubMed Web of Science ®Google Scholar

Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53. doi: 10.1053/jinf.2002.0978.

 PubMed Web of Science ®Google Scholar

Hamdi AM, Fida M, Abu Saleh OM, et al. Stenotrophomonas bacteremia antibiotic susceptibility and prognostic determinants: Mayo Clinic 10-year experience. Open Forum Infect Dis. 2020;7(1):ofaa008. doi: 10.1093/ofid/ofaa008.

 PubMed Web of Science ®Google Scholar

Hashimoto T, Komiya K, Fujita N, et al. Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteraemia. Infect Dis. 2020;52(6):440–442. doi: 10.1080/23744235.2020.1734653.

 PubMed Web of Science ®Google Scholar

Jeon YD, Jeong WY, Kim MH, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine. 2016;95(31):e4375. doi: 10.1097/MD.0000000000004375.

 PubMed Web of Science ®Google Scholar

Jian J, Xie Z, Chen L. Risk factors for mortality in hospitalized patients with Stenotrophomonas maltophilia bacteremia. Infect Drug Resist. 2022;15:3881–3886. doi: 10.2147/IDR.S371129.

 PubMed Web of Science ®Google Scholar

Kanchanasuwan S, Rongmuang J, Siripaitoon P, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. J Clin Med. 2022;11(11):3085. doi: 10.3390/jcm11113085.

 PubMed Web of Science ®Google Scholar

Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49(9):3980–3981. doi: 10.1128/AAC.49.9.3980-3981.2005.

 PubMed Web of Science ®Google Scholar

Sumida K, Chong Y, Miyake N, et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLOS One. 2015;10(7):e0133731. doi: 10.1371/journal.pone.0133731.

 PubMed Web of Science ®Google Scholar

Watson L, Esterly J, Jensen AO, et al. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections. J Glob Antimicrob Resist. 2018;12:104–106. doi: 10.1016/j.jgar.2017.09.015.

 PubMed Web of Science ®Google Scholar

Data availability statement

The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.